148 related articles for article (PubMed ID: 38439189)
1. Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences.
Oh JH; Jun DW
Clin Mol Hepatol; 2024 Apr; 30(2):168-170. PubMed ID: 38439189
[No Abstract] [Full Text] [Related]
2. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
3. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38725327
[TBL] [Abstract][Full Text] [Related]
5. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
6. Correspondence on Letter regarding "Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study".
Fujii H; Iwaki M; Kamada Y
Clin Mol Hepatol; 2024 Apr; 30(2):281-283. PubMed ID: 38606425
[No Abstract] [Full Text] [Related]
7. Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study.
Jung YM; Lee SM; Wi W; Oh MJ; Park JS; Cho GJ; Kim W
JHEP Rep; 2024 Apr; 6(4):101033. PubMed ID: 38524668
[TBL] [Abstract][Full Text] [Related]
8. Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease.
Cheng WC; Wong PY; Wu CD; Cheng PN; Lee PC; Li CY
Environ Health Prev Med; 2024; 29():7. PubMed ID: 38346730
[TBL] [Abstract][Full Text] [Related]
9. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
10. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
11. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease.
Romeo S; Jamialahmadi O; De Vincentis A; Tavaglione F; Malvestiti F; Li-Gao R; Mancina R; Alvarez M; Gelev K; Maurotti S; Vespasiani-Gentilucci U; Rosendaal F; Kozlitina J; Pajukanta P; Pattou F; Valenti L
Res Sq; 2024 Feb; ():. PubMed ID: 38405802
[TBL] [Abstract][Full Text] [Related]
12. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
13. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies for MASLD and their impact on plasma lipids.
Nguyen M; Asgharpour A; Dixon DL; Sanyal AJ; Mehta A
Am J Prev Cardiol; 2024 Mar; 17():100638. PubMed ID: 38375066
[TBL] [Abstract][Full Text] [Related]
15. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
[TBL] [Abstract][Full Text] [Related]
16. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
Chen L
World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
[TBL] [Abstract][Full Text] [Related]
17. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
18. Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES.
Wu Y; Tan Z; Zhen J; Liu C; Zhang J; Liao F; Dong W
BMC Public Health; 2023 Nov; 23(1):2286. PubMed ID: 37985986
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
[No Abstract] [Full Text] [Related]
20. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome.
Xu Q; Zhang J; Lu Y; Wu L
iScience; 2024 Feb; 27(2):108783. PubMed ID: 38292434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
